NCT05426252View on ClinicalTrials.gov

Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Thalassemia in Children
Interventions
DRUG

Abatacept

Abatacept, co-stimulation blockade, to be given for GVHD prophylaxis in combination with sirolimus post allogeneic hematopoietic stem cell transplantation.

DRUG

Sirolimus

Sirolimus, mTOR inhibitor, to be given for GVHD prophylaxis in combination with abatacept post allogeneic hematopoietic stem cell transplantation.

Trial Locations (1)

Unknown

RECRUITING

Yogi Chopra, Toronto

All Listed Sponsors
collaborator

Thalassemia Foundation of Canada

UNKNOWN

lead

The Hospital for Sick Children

OTHER